- Presentation Will Highlight Positive Clinical Trial Data on iNexin™ for Treatment of Corneal Injury - - Xequel Launches New...
SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the...
Bentrio USA Altamira Therapeutics Re-launches Bentrio in Europe for Allergic RhinitisHAMILTON, BERMUDA , Sept. 27, 2022 (GLOBE NEWSWIRE) -- BentrioTM...
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr....
New study size of 140 patients for the REBUILD Study, without modifying trial objective or endpoints and maintaining power of...
ISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working...
Akari successfully closed a registered direct offering and concurrent private placement raising aggregate gross proceeds of approximately $12.8 millionFinancing supports...
REHOVOT, Israel and WILMINGTON, Del., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company...
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA oncology company committed to more effectively...
ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing...
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine ResearchPRINCETON, N.J.,...
- The DSMC has reviewed the safety and pharmacokinetic data from Cohort 1 and recommended that the study may proceed...
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered...
NEW YORK, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on...
PNV-5030 significantly reduced pain compared to both placebo and acetaminophen PNV-5030 - Chronic Constrictive Injury Model (Rat) PNV-5030 - Chronic...
ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...
KELOWNA, British Columbia, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"),...
PALO ALTO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the...
WOBURN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of...
– Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta)...